September 20 2023
This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
August 29 2023
This award funds DZD's development of epiXact®FMT, a pharmacovigilance assay to enhance safety and efficacy in fecal microbiota transplant (FMT) clinical trials.
November 9 2022
DZD announced that Gail Marcus has joined the company’s Board of Directors as an independent director
October 20 2022
DZD Will Continue Clinical Validation and Product Engineering of its Novel Technology Designed to Reduce Time to Diagnosis from Days to Hours
August 25 2022
Dr. Amy Mathers and Rob Crisp Bring Extensive Academic and Industry Experience
April 8 2022
Providing Whole Genome Sequencing Based Services for High Impact Clinical Decisions